Pharmaceutical formulation design affects patient acceptability/adherence and pharmacokinetics of the drug. This is particularly important for older patients because of the physiological changes due to ageing and clinical/social circumstances related to medicine taking.This book provides a comprehensive review in the design of formulations to meet the needs of older patients. An overview of the key clinical, social and pharmaceutical factors affecting medication optimization, safety and acceptability in older adults is included, followed by patient-centric considerations including regulatory requirements, dosage form design and human factor studies.Advanced pharmaceutical technologies are discussed for their potential use in older adults such as 3D printing, long-acting oral formulations and novel vaccine technologies. The unique focus of the book will be of interest to pharmaceutical scientists in both industryand academia in searching for better formulations for older patients.
Les mer
Part 1: Patient-Centric Considerations.-Medicine Optimisation in Older .- Acceptability of drug formulations in older patients and effect on patient adherence.- Geriatric biopharmaceutics.- Excipient safety in older adults.- Part 2: Pharmaceutical Formulations Development for older Patients.- Oral and oromucosal formulation development and in vitro characterisation – patient-centric approaches for older adults.- Pulmonary drug delivery systems for older people.- Transdermal drug delivery systems for older patients.- Part 3 :Advanced Drug Delivery Systems for Older Patients.- Advanced oral drug delivery systems for older patients.- The ageing microbiome, pharmaceutical considerations and therapeutic opportunities.- Application of 3D printing in geriatric medicines,.- Application of electrospraying and advanced fabrication methods in geriatric medicines.- Vaccine development for older patients.
Les mer
Pharmaceutical formulation design affects patient acceptability/adherence and pharmacokinetics of the drug. This is particularly important for older patients because of the physiological changes due to ageing and clinical/social circumstances related to medicine taking.This book provides a comprehensive review in the design of formulations to meet the needs of older patients. An overview of the key clinical, social and pharmaceutical factors affecting medication optimization, safety and acceptability in older adults is included, followed by patient-centric considerations including regulatory requirements, dosage form design and human factor studies.Advanced pharmaceutical technologies are discussed for their potential use in older adults such as 3D printing, long-acting oral formulations and novel vaccine technologies. The unique focus of the book will be of interest to pharmaceutical scientists in both industry and academia in searching for better formulations for older patients.
Les mer
Provides a better understanding on the EMA reflection paper on pharmaceutical development for older patients Details reasons for applying advanced pharmaceutical technologies for the benefit of the ageing population Discusses Advanced pharmaceutical technologies for their potential use in older adults for medication optimization
Les mer
Produktdetaljer
ISBN
9783031358135
Publisert
2024-11-11
Utgiver
Vendor
Springer International Publishing AG
Høyde
235 mm
Bredde
155 mm
Aldersnivå
Research, P, 06
Språk
Product language
Engelsk
Format
Product format
Heftet
Om bidragsyterne
Professor Mine Orlu
Mine Orlu is Professor of Pharmaceutics and MSc Pharmaceutics, Programme Director in the UCL School of Pharmacy. Professor Orlu`s research focuses on clinical pharmaceutics in particular designing pharmaceutical formulations tailored considering the physiological alterations and medicine administration related needs occurring at advanced age. Professor Orlu has published over 100 papers in leading journals of pharmaceutics. She is one of the World Economic Forum (WEF)'s Young Scientists (Class of 2020). Professor Fang LiuFang Liu is Professor of Pharmaceutics in the Department of Clinical Pharmaceutical and Biological Science at University of Hertfordshire. Fang’s research interest is in the development of age-appropriate medicines for children and older patients especially using oral solid dosage forms. She is the Founder Director of Fluid Pharma Ltd, a University of Hertfordshire spin out to advance paediatric and geriatric medicine development. Fang is the co-chair of Age-related Medicines Focus Group in the Academy of Pharmaceutical Sciences of Great Britain and a member of the European Paediatric Formulation Initiative.